International Journal of Drug Policy Volume 47, Pages 1-246, September 2017

HCV care among PWID

Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy    Pages 26-33 Jason Grebely, Julie Bruneau, Philip Bruggmann, Magdalena Harris, Matthew Hickman, Tim Rhodes, Carla Treloar, on behalf of the International Network on Hepatitis in Substance Users, on behalf of the International Network on Hepatitis in Substance Users

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review    Original Research Article Pages 34-46 Sahar Bajis, Gregory J. Dore, Behzad Hajarizadeh, Evan B. Cunningham, Lisa Maher, Jason Grebely

Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses    Pages 47-50 J.V. Lazarus, K. Safreed-Harmon, S.R. Stumo, M. Jauffret-Roustide, M. Maticic, T. Reic, E. Schatz, J. Tallada, M. Harris, on behalf of the Hep-CORE Study Group

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs    Pages 51-60 Jason Grebely, Julie Bruneau, Jeffrey V. Lazarus, Olav Dalgard, Philip Bruggmann, Carla Treloar, Matthew Hickman, Margaret Hellard, Teri Roberts, Levinia Crooks, Håvard Midgard, Sarah Larney, Louisa Degenhardt, Hannu Alho, Jude Byrne, John F. Dillon, Jordan J. Feld, Graham Foster, David Goldberg, Andrew R. Lloyd, et al.

High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention    Original Research Article Pages 61-68 Svetlana Puzhko, Élise Roy, Didier Jutras-Aswad, Andreea Adelina Artenie, Emmanuel Fortier, Geng Zang, Julie Bruneau

Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996–2015    Original Research Article Pages 69-76 Simon Graham, Lisa Maher, Handan Wand, Michael Doyle, Jenny Iversen

Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia    Original Research Article Pages 77-85 Jenny Iversen, Jason Grebely, Beth Catlett, Philip Cunningham, Gregory J. Dore, Lisa Maher

Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs    Original Research Article Pages 86-94 Dustin B. Stephens, April M. Young, Jennifer R. Havens

HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985–2015    Original Research Article Pages 95-101 Daniëla K. van Santen, Jannie J. van der Helm, Karen Lindenburg, Maarten Schim van der Loeff, Maria Prins

Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia    Original Research Article Pages 102-106 Kerryn Butler, Carolyn Day, Rachel Sutherland, Joe van Buskirk, Courtney Breen, Lucinda Burns, Sarah Larney

Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade    Original Research Article Pages 107-116 Nick Scott, Joseph S. Doyle, David P. Wilson, Amanda Wade, Jess Howell, Alisa Pedrana, Alexander Thompson, Margaret E. Hellard

Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands    Original Research Article Pages 117-125 Charles W. Helsper, Mart P. Janssen, Gerrit A. van Essen, Esther A. Croes, Clary van der Veen, Ardine G. de Wit, Niek J. de Wit

DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy    Original Research Article Pages 126-136 Andrew Radley, Jan Tait, John F. Dillon

Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals    Original Research Article Pages 137-143 Allison Mah, Mark W. Hull, Kora DeBeck, Michael John Milloy, Sabina Dobrer, Ekaterina Nosova, Evan Wood, Thomas Kerr, Kanna Hayashi

Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia    Original Research Article Pages 144-152 Trena I. Mukherjee, Veena Pillai, Siti Hafizah Ali, Frederick L. Altice, Adeeba Kamarulzaman, Jeffrey A. Wickersham

‘I didn’t want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study    Original Research Article Pages 153-160 Alison D. Marshall, Jason Grebely, Gregory J. Dore, Carla Treloar

Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment ‘benefit’    Original Research Article Pages 161-168 Magdalena Harris

Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?    Original Research Article Pages 169-176 Dimitra Panagiotoglou, Emanuel Krebs, Jeong Eun Min, Michelle Olding, Keith Ahamad, Lianping Ti, Julio S.G. Montaner, Bohdan Nosyk

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study    Original Research Article Pages 177-186 Jason Grebely, Olav Dalgard, Evan B. Cunningham, Behzad Hajarizadeh, Graham R. Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Janaki Amin, Philippa S. Marks, Sophie Quiene, Tanya L. Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Margaret Hellard, Julie Bruneau, Håvard Midgard, et al.

Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes    Original Research Article Pages 187-195 Alyona Mazhnaya, Anna Meteliuk, Tetiana Barnard, Alexei Zelenev, Sergii Filippovych, Frederick L. Altice

High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic    Original Research Article Pages 196-201 Brianna L. Norton, Julia Fleming, Marcus A. Bachhuber, Meredith Steinman, Joseph DeLuca, Chinazo O. Cunningham, Nirah Johnson, Fabienne Laraque, Alain H. Litwin

Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada    Original Research Article Pages 202-208 Kate Mason, Zoë Dodd, Mary Guyton, Paula Tookey, Bernadette Lettner, John Matelski, Sanjeev Sockalingam, Jason Altenberg, Jeff Powis

Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting    Original Research Article Pages 209-215 Phillip Read, Rebecca Lothian, Karen Chronister, Rosie Gilliver, John Kearley, Gregory J. Dore, Ingrid van Beek

Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors’ Health Network    Original Research Article Pages 216-220 Leith Morris, Andrew Smirnov, Amanda Kvassay, Ellen Leslie, Rebecca Kavanagh, Nik Alexander, Geoff Davey, Owain Williams, Charles Gilks, Jake Najman

Tensions in relation: How peer support is experienced and received in a hepatitis C treatment intervention    Original Research Article Pages 221-229 Oliver Bonnington, Magdalena Harris

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study    Original Research Article Pages 230-238 Håvard Midgard, Behzad Hajarizadeh, Evan B. Cunningham, Brian Conway, Markus Backmund, Philip Bruggmann, Julie Bruneau, Stefan Bourgeois, Adrian Dunlop, Graham R. Foster, Margaret Hellard, Geert Robaeys, Maria C. Thurnheer, Martin Weltman, Janaki Amin, Philippa S. Marks, Sophie Quiene, Gregory J. Dore, Olav Dalgard, Jason Grebely, et al.

Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection    Original Research Article Pages 239-243 Andreea Adelina Artenie, Geng Zang, Mark Daniel, Emmanuel Fortier, Didier Jutras-Aswad, Svetlana Puzhko, Julie Bruneau

Research Papers

Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada    Original Research Article Pages 1-8 Rielle Capler, Zach Walsh, Kim Crosby, Lynne Belle-Isle, Susan Holtzman, Philippe Lucas, Robert Callaway

Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California    Original Research Article Pages 9-17 Danielle Horyniak, Karla D. Wagner, Richard F. Armenta, Jazmine Cuevas-Mota, Erik Hendrickson, Richard S. Garfein

Animal house: University risk environments and the regulation of students’ alcohol use    Original Research Article Pages 18-25 Blair Wilkinson, Andrew Ivsins

Call for Paper: Themed Collection: Sexualised drug use: LGBT communities and beyond    Page 244

Call for Papers Themed Collection Parents and substance use; management of risky parenthood    Page 245